Condition

Marginal Zone Lymphoma clinical trials and research

• 41Clinical trials
• 20Countries

Newest Marginal Zone Lymphoma clinical trials

All recruiting trials (41)

• Nemtabrutinib plus rituximab for marginal zone lymphoma

  This phase 2 trial tests whether combining nemtabrutinib with rituximab can help people with marginal zone lymphoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07583810

• Orelabrutinib for adults with early-stage untreated marginal zone lymphoma

  This trial will try orelabrutinib, a selective oral BTK inhibitor, as first-line treatment for adults with stage I–II marginal zone lymphoma to see if it works and is safe.

  Recruiting at 14 sites Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Guangzhou, Guangdong and 13 other locations · NCT07441993

• Zanubrutinib plus rituximab as first-line treatment for marginal zone lymphoma

  This tests whether combining zanubrutinib and rituximab is effective and safe as first-line treatment for people with CD20-positive marginal zone lymphoma who have not received prior systemic therapy.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07233720

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Reduced-dose radiation therapy for people with follicular or marginal zone lymphoma

  This trial will test whether very low-dose radiation controls stage I–II follicular or marginal zone lymphoma as well as standard-dose radiation while causing fewer side effects.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07029217

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Epcoritamab for newly diagnosed marginal zone lymphoma

  This trial will test whether the antibody drug epcoritamab helps adults who are newly diagnosed with marginal zone lymphoma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06796998

• Tafasitamab with lenalidomide and rituximab for newly diagnosed follicular and marginal zone lymphoma

  This trial will test whether adding tafasitamab to rituximab and lenalidomide is safe and helps people newly diagnosed with follicular lymphoma or marginal zone lymphoma.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06792825

• Orelabrutinib and Obinutuzumab for Treating Marginal Zone Lymphoma

  This study is testing a new treatment combining Orelabrutinib and Obinutuzumab for people with previously untreated Marginal Zone Lymphoma to see if it works better and is safer than traditional chemotherapy.

  Recruiting Phase 2 Huai'an First People's Hospital · Huai'an, Jiangsu · NCT06566807

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Registry of Chinese Patients with Marginal Zone Lymphoma

  This study looks at how Chinese patients with marginal zone lymphoma are treated in real life to see how well those treatments work and how they affect patients' quality of life.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06534463

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Rituximab plus venetoclax as first treatment for marginal zone lymphoma

  This trial will test whether combining rituximab and venetoclax helps adults with previously untreated marginal zone lymphoma.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT06510309

• Orelabrutinib combined with BR/G for untreated Marginal Zone Lymphoma

  This study is testing if a new drug called Orelabrutinib, combined with other treatments, can help younger and older patients with untreated Marginal Zone Lymphoma feel better and have fewer side effects.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06504940

• Combining Orelabrutinib and Rituximab for Treating Marginal Zone Lymphoma

  This study is testing if combining two medications, Orelabrutinib and Rituximab, can help adults with Marginal Zone Lymphoma who haven't responded to other treatments or can't have local therapy.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06478472

• Combination treatment for marginal zone lymphoma

  This study is testing a new combination of three medications to see if it can help people with untreated marginal zone lymphoma get better.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06454968

• Observing newly diagnosed marginal zone lymphoma patients

  This study looks at newly diagnosed marginal zone lymphoma patients to see how the disease behaves and how different treatments work for them.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06449885

• Combining Pirtobrutinib and Rituximab for treating newly diagnosed Marginal Zone Lymphoma

  This study is testing if combining two medications, Pirtobrutinib and Rituximab, can help people who have just been diagnosed with marginal zone lymphoma feel better.

  Recruiting at 2 sites Phase 2 University of Utah · St Louis, Missouri and 1 other locations · NCT06390956

• Combining rituximab and zanubrutinib for treating indolent B-cell lymphomas

  This study is testing if combining two medications, rituximab and zanubrutinib, can help people with untreated indolent B-cell lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06350318

• Using CAR T cells to treat certain types of B cell lymphomas

  This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06340737

• Seeing CXCR4 in lymphoma and leukemia with a new PET tracer

  This study tests a new PET tracer called 18F-BL40 to see if it can image CXCR4-expressing cancers and compares it with the standard 18F-FDG in adults with various blood cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06224309

• Evaluating blood pressure management in patients with B-cell cancers on specific treatments

  This study is trying to see how blood pressure changes in people with B-cell cancers who are being treated with a specific type of medication, and what the best ways are to manage any high blood pressure they might develop.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06151730

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Comparing Mosunetuzumab-Lenalidomide to other treatments for relapsed or refractory Marginal Zone Lymphoma

  This study is testing if a new combination of Mosunetuzumab and Lenalidomide can help people with relapsed or refractory Marginal Zone Lymphoma feel better compared to other standard treatments they might have already tried.

  Recruiting at 26 sites Phase 3 The Lymphoma Academic Research Organisation · Anderlecht and 47 other locations · NCT06006117

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Combining obinutuzumab and lenalidomide for treating relapsed marginal zone lymphoma

  This study is testing a combination of two medications, obinutuzumab and lenalidomide, to see if they can help people with relapsed marginal zone lymphoma feel better.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tian · NCT05846750

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Evaluating zanubrutinib treatment in patients with certain blood cancers

  This study is trying to see how well zanubrutinib works and how it affects the lives of adults with certain blood cancers like Waldenström's Macroglobulinemia and Chronic Lymphocytic Leukemia.

  Recruiting at 2 sites iOMEDICO AG · Salzburg and 1 other locations · NCT05326308

• Treatment with Loncastuximab Tesirine for Relapsed Marginal Zone Lymphoma

  This study is testing a new drug called loncastuximab tesirine to see if it helps people with relapsed marginal zone lymphoma feel better after other treatments haven't worked.

  Recruiting at 4 sites Phase 2 University of Miami · Duarte, California and 3 other locations · NCT05296070

• Treatment for B-cell malignancies using BGB-16673

  This study is testing a new drug called BGB-16673 to see if it can safely help people with different types of B-cell cancers.

  Recruiting at 29 sites Phase 1/2 BeOne Medicines · Bengbu, Anhui and 28 other locations · NCT05294731

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Combining acalabrutinib and obinutuzumab to treat untreated follicular lymphoma and indolent non-Hodgkin lymphomas

  This study is testing if combining two treatments, acalabrutinib and obinutuzumab, can help people with untreated follicular lymphoma and other slow-growing non-Hodgkin lymphomas feel better and improve their quality of life.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT04883437

• First-line treatment for follicular and marginal zone lymphoma using mosunetuzumab and lenalidomide

  This study is testing if a new combination of treatments can help adults with untreated follicular or marginal zone lymphoma feel better and improve their response to therapy.

  Recruiting at 2 sites Phase 2 Brown University · New Haven, Connecticut and 2 other locations · NCT04792502

• Oral treatment with LP-168 for patients with certain blood cancers

  This study is testing an oral treatment called LP-168 to see if it can help adults with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 4 sites Phase 1 Newave Pharmaceutical Inc · Durham, North Carolina and 3 other locations · NCT04775745

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

Related topics

Quick answers

How many Marginal Zone Lymphoma clinical trials are recruiting right now?

41, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 20 countries. The most sites are in United States (28 trials), China (11 trials), Germany (3 trials), France (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 17, Phase 1: 7, Phase 1/2: 6, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →